South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case
A landmark South African legal complaint against British drug maker GlaxoSmithKline (
GSK) over its AIDS drug pricing and policies in that country will proceed following an order late last week by South Africa's Competition Tribunal that will allow the complaint to go forward.
GSK has sought outright dismissal of the case; however, the Competition Tribunal issued an order last week giving the comp...
GSK at Biology Products
GSK at Biology Technology
GSK at Medicine News
Rejuvenation of Stem cells by GSK-3 Inhibitor
Professor Mick Bhatia and his team from Robarts Research Institute have found that supplementation of
GSK-3 Inhibitors with Cord blood regenerates the immune system to produce immune cells which fights against cancer cells.// Researchers have found that this drug
GSK-3 which is used in the treatment of Alzheimer’s and diabetes to boost the immune cells without causing any toxicity or side...
GSK’s New Anticancer Drug A Huge Success In Drug trail
Tykerb, the new experimental breast cancer treatment drug has proved so well in the drug trails, that based on its success alone the drug might be made //available to patients in the late stages of the disease even before it is approved by the regulators. It is speculated that Europe's largest drug maker is all set to dominate the world's biggest cancer conference in Atlanta today wit...
China to make cheaper version of GSK’s flu dru
GlaxoSmithKline signed an agreement with Simcere Pharmaceutical Group of Nanjing, China for it to manufacture and sell a cheaper version of its flu drug Relenza in poor countries//. The Chinese company can manufacture and sell zanamivir in China, Indonesia, Thailand, Vietnam and all least-developed countries, under the terms of licensing agreement. "
GSK is doing everything we...
GSK Seeks Permission to Market Breast Cancer Pill Tykerb
GlaxoSmithKline PLC has filed for permission with European medicine regulators to begin selling its new breast cancer pill Tykerb//. This follows a similar move in the US last month, and comes slightly earlier than some commentators were expecting. The drug is foreseen to be one of
GSK's most promising pipeline drugs as well as a potential blockbuster. According to analyst...
GSK, TCS to Jointly Set Up Drug Development Center
Pharma major GlaxoSmithKline (
GSK) and global IT giant Tata Consultancy Services (TCS) have entered //into a multi-million dollar contract for setting up a global drug development center in Mumbai. Under the contract, TCS will provide a variety of services in clinical research, including clinical data management and clinical submissions support. "
GSK has chosen to part...
More>>
GSK at Medicine Products
GSK at Medicine Technology
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age
New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(
GSK) cervical cancer candidate vaccine had antibodies pr...
Encouraging Clinical Activity of GSK's Novel Cancer
Immunotherapeutic Confirmed in Phase II Study in Patients with Most
Common Form of Lung Cancer
GSK Announces Launch of Largest Ever Phase III Clinical Trial inLung Cancer Treatment PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline today announced final results of a Phase IIproof-of-concept clinical trial of its investigational MAGE-A3Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3positive patients with stage IB or II Non-Small Cell Lung Cancer(NSCLC)...
GSK'S Pazopanib Shows Positive Results in Patients with Advanced
Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline todayannounced results from ongoing Phase II studies of pazopanib inadvanced or metastatic renal cell carcinoma (RCC), ovarian cancerand soft tissue sarcoma (STS). These trials were presented at the43rd Annual Meeting of the American Society of Clinical Oncology(ASCO) in Chicago. The results observed in these trials withpazopanib sup...
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years
New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...
GSK and Adolor Announce Preliminary Results from Phase 3 Safety
Study of Alvimopan (Entereg/Entrareg)
LONDON & EXTON, Pa.--(BUSINESS WIRE)--Apr 9, 2007 -GlaxoSmithKline (LSE and NYSE:
GSK) and Adolor Corporation(Nasdaq:ADLR) today announced data from Study 767905/014 andprovided an update on the clinical development program foralvimopan (Entereg/Entrareg(R)). Study 014, a Phase 3, double blind, placebo-controlled (12month) study, was designed to evaluate the long-term safety andtolera...